摘要
中成药制造业是高新技术产业,其产业经济的提升需要持续投入研发资源。中成药制造业的经济发展离不开制药企业的研发创新活动。为科学、有效地评价中成药企业的研发效率,利用上市企业市场份额占比高、数据透明度好等特点,以21家中成药上市企业为对象,运用数据包络分析法分别从静态和动态2个方面评价研发效率。研究表明,21家中成药上市企业在2015—2018年的研发综合平均有效率仅为65.7%,规模平均有效率较低(71.1%)是主要影响因素。从曼奎斯特指数(M指数)看,生产率呈下降趋势的中成药上市企业占61.9%,这可能是影响中成药行业近年来经济下行的重要因素之一。由此建议,中成药企业应重视企业研发活动的效率问题,合理分配研发资源,通过扩大研发规模、利用技术进步带动研发效率的提升。
The Chinese patent medicine manufacturing industry is a high-tech industry,and its industrial economic improvement requires continuous input in research and development(R&D)resources to obtain output.The economic development of Chinese patent medicine manufacturing industry is inseparable from the R&D and innovation activities of pharmaceutical companies.In order to scientifically and effectively evaluate the research and development efficiency of Chinese patent medicine companies,combined with the characteristics of listed companies′high market share and good data transparency,21 listed Chinese patent medicine companies are targeted at using data envelopment analysis(DEA)to evaluate R&D efficiency from static and dynamic aspects.The research showed that the average R&D efficiency of the 21 listed Chinese patent medicine enterprises was only 65.7%from 2015 to 2018,mainly due to the low average scale efficiency(71.1%).From the perspective of the M index,61.9%of listed Chinese patent medicine companies have had a downward trend in productivity,which may be one of the important factors affecting the economic downturn of the Chinese patent medicine industry in recent years.Therefore,it is recommended that Chinese patent medicine enterprises should pay attention to the efficiency of R&D activities of enterprises,allocate R&D resources reasonably,and promote the improvement of R&D efficiency by expanding the scale of R&D and using technological progress.
作者
金安琪
杨光
李斐琳
程蒙
阙灵
宋涛
陈敏
JIN An-qi;YANG Guang;LI Fei-lin;CHENG Meng;QUE Ling;SONG Tao;CHEN Min(National Resource Center for Chinese Materia Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;School of Economics and Resource Management,Beijing Normal University,Beijing 100875,China)
出处
《中国现代中药》
CAS
2021年第4期719-726,共8页
Modern Chinese Medicine
基金
国家社科基金一般项目(19BJL046)。
